BRPI0708490B8 - composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto - Google Patents

composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto

Info

Publication number
BRPI0708490B8
BRPI0708490B8 BRPI0708490A BRPI0708490A BRPI0708490B8 BR PI0708490 B8 BRPI0708490 B8 BR PI0708490B8 BR PI0708490 A BRPI0708490 A BR PI0708490A BR PI0708490 A BRPI0708490 A BR PI0708490A BR PI0708490 B8 BRPI0708490 B8 BR PI0708490B8
Authority
BR
Brazil
Prior art keywords
compound
compounds
preparing
formula
opioid receptor
Prior art date
Application number
BRPI0708490A
Other languages
English (en)
Inventor
Roland Saito Daisuke
D Long Daniel
Stergiades Ioanna
R Jacobsen John
Jiang Lan
Preza Leticia
Van Dyke Priscilla
M Dalziel Sean
J Church Timothy
Original Assignee
Theravance Biopharma R&D Ip Llc
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38436795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0708490(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Biopharma R&D Ip Llc, Theravance Inc filed Critical Theravance Biopharma R&D Ip Llc
Publication of BRPI0708490A2 publication Critical patent/BRPI0708490A2/pt
Publication of BRPI0708490B1 publication Critical patent/BRPI0708490B1/pt
Publication of BRPI0708490B8 publication Critical patent/BRPI0708490B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

compostos de 8-azabiciclo[3.2.1] octano como antagonista de receptor opióide mu. a invenção fornece novos compostos de 8-azabiciclo[3.2.1]octano da fórmula (i), onde r1, r2, r3, a e g são definidos no relatório, ou um sal ou solvato deste farmaceuticamente aceitáveis, que são antagonistas ao receptor opióide mu. a invenção também fornece composições farmacêuticas compreendendo tais compostos, métodos de uso de tais compostos para tratar doenças associadas com a atividade do receptor opióide mu, e processos e intermediários úteis para preparar tais compostos.
BRPI0708490A 2006-03-01 2007-02-28 composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto BRPI0708490B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77796206P 2006-03-01 2006-03-01
US60/777/962 2006-03-01
US84102806P 2006-08-30 2006-08-30
US60/841.028 2006-08-30
PCT/US2007/005388 WO2007103187A2 (en) 2006-03-01 2007-02-28 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Publications (3)

Publication Number Publication Date
BRPI0708490A2 BRPI0708490A2 (pt) 2011-05-31
BRPI0708490B1 BRPI0708490B1 (pt) 2019-07-30
BRPI0708490B8 true BRPI0708490B8 (pt) 2021-05-25

Family

ID=38436795

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0708490A BRPI0708490B8 (pt) 2006-03-01 2007-02-28 composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto

Country Status (25)

Country Link
US (11) US7622508B2 (pt)
EP (1) EP2001876B1 (pt)
JP (2) JP5086280B2 (pt)
KR (1) KR101376479B1 (pt)
AR (1) AR059690A1 (pt)
AT (1) ATE509928T1 (pt)
AU (1) AU2007224213B2 (pt)
BR (1) BRPI0708490B8 (pt)
CA (1) CA2646409C (pt)
CY (1) CY1111747T1 (pt)
DK (1) DK2001876T3 (pt)
HK (1) HK1125935A1 (pt)
HR (1) HRP20110590T1 (pt)
IL (1) IL193690A (pt)
MA (1) MA30284B1 (pt)
MX (1) MX2008011165A (pt)
MY (1) MY145633A (pt)
NZ (1) NZ570764A (pt)
PE (1) PE20071311A1 (pt)
PL (1) PL2001876T3 (pt)
PT (1) PT2001876E (pt)
RU (1) RU2423362C2 (pt)
SI (1) SI2001876T1 (pt)
TW (1) TWI379832B (pt)
WO (1) WO2007103187A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI415850B (zh) * 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ES2465621T3 (es) * 2007-08-27 2014-06-06 Theravance, Inc. Compuestos de heteroarilalquil-8-azabiciclo[3.2.1]octano, como antagonistas de los receptores opiodes mu
WO2009029252A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
WO2011035142A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
EP2423210A1 (de) 2010-08-25 2012-02-29 Bayer CropScience AG Heteroarylpiperidin- und -piperazinderivate als Fungizide
WO2012055837A1 (de) 2010-10-27 2012-05-03 Bayer Cropscience Ag Heteroarylpiperidin und -piperazinderivate als fungizide
JP5703009B2 (ja) * 2010-12-16 2015-04-15 住友精化株式会社 スルホン化合物、スルホン化合物の製造方法、および電気化学デバイス用電解液
JP6326231B2 (ja) 2011-02-01 2018-05-16 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺菌剤としてのヘテロアリールピペリジン誘導体及びヘテロアリールピペラジン誘導体
MX355824B (es) 2011-09-15 2018-05-02 Bayer Ip Gmbh Piperidinpirazoles como fungicidas.
EP2921495B1 (de) 2011-12-27 2018-03-28 Bayer Intellectual Property GmbH Heteroarylpiperidin und -piperazinderivate als fungizide
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
AU2016243691A1 (en) 2015-04-02 2017-10-12 Theravance Biopharma Randd Ip, LLC Combination dosage form of a mu opioid receptor antagonist and an opioid agent
KR20200136384A (ko) 2018-02-05 2020-12-07 알케르메스, 인코포레이티드 통증 치료용 화합물
CA3196642A1 (en) * 2020-11-06 2022-05-12 Christian GRUGEL Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1067824B (de) * 1954-10-20 1959-10-29 Sandoz Ag Verfahren zur Herstellung saeureamidartiger Tropanabkoemmlinge
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US6900228B1 (en) 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
GB9810671D0 (en) 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US20030181447A1 (en) 2001-02-22 2003-09-25 Boyd Robert E. 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
CN1426411A (zh) 2000-03-03 2003-06-25 奥索-麦克尼尔药品公司 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物
US20020025948A1 (en) 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
EP1443046B1 (en) 2001-10-09 2008-12-17 Kyorin Pharmaceutical Co., Ltd. Novel 4-(2furoyl)aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
JP4155522B2 (ja) 2001-10-22 2008-09-24 ファイザー・プロダクツ・インク オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
MXPA05011070A (es) 2003-04-14 2005-12-12 Pfizer Prod Inc Derivados de 3-azabiciclo [3.2.1] octano.
US20040204453A1 (en) 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
US7056930B2 (en) 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
EP1615920A1 (en) 2003-04-15 2006-01-18 Pfizer Products Inc. 3-benzhydrylidene-8-aza-bicyclo [3.2.1] octane derivatives with opioid receptor activity
US6992090B2 (en) 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US7435822B2 (en) 2004-02-03 2008-10-14 Janssen Pharmaceutica N.V. 3-(diheteroarylmethylene)-8-azabicyclo[3.2.1]octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane derivatives
US7087749B2 (en) 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
US20100284960A1 (en) 2006-11-07 2010-11-11 Nektar Therapeutics Al, Corporation Dosage Forms and Co-Administration of Opioid Agonist and Opioid Antagonist
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI415850B (zh) 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
US7947710B2 (en) 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2009029252A1 (en) 2007-08-27 2009-03-05 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ES2465621T3 (es) 2007-08-27 2014-06-06 Theravance, Inc. Compuestos de heteroarilalquil-8-azabiciclo[3.2.1]octano, como antagonistas de los receptores opiodes mu

Also Published As

Publication number Publication date
JP5086280B2 (ja) 2012-11-28
SI2001876T1 (sl) 2011-09-30
EP2001876B1 (en) 2011-05-18
US10377751B2 (en) 2019-08-13
BRPI0708490B1 (pt) 2019-07-30
TWI379832B (en) 2012-12-21
HRP20110590T1 (hr) 2011-09-30
US20070219278A1 (en) 2007-09-20
AR059690A1 (es) 2008-04-23
KR20080100282A (ko) 2008-11-14
PT2001876E (pt) 2011-08-18
RU2423362C2 (ru) 2011-07-10
US10745394B2 (en) 2020-08-18
US8664242B2 (en) 2014-03-04
JP2009528371A (ja) 2009-08-06
IL193690A0 (en) 2009-08-03
US20170349578A1 (en) 2017-12-07
US20210024515A1 (en) 2021-01-28
TW200800981A (en) 2008-01-01
CY1111747T1 (el) 2015-10-07
IL193690A (en) 2013-02-28
EP2001876A2 (en) 2008-12-17
US11548887B2 (en) 2023-01-10
US20140288112A1 (en) 2014-09-25
US20190119267A1 (en) 2019-04-25
DK2001876T3 (da) 2011-08-29
RU2008138875A (ru) 2010-04-10
US20230183232A1 (en) 2023-06-15
US9206172B2 (en) 2015-12-08
US20100035921A1 (en) 2010-02-11
US8927573B2 (en) 2015-01-06
JP2012211193A (ja) 2012-11-01
PL2001876T3 (pl) 2011-10-31
US20150291579A1 (en) 2015-10-15
US20190308966A1 (en) 2019-10-10
CA2646409C (en) 2015-11-10
BRPI0708490A2 (pt) 2011-05-31
WO2007103187A2 (en) 2007-09-13
MY145633A (en) 2012-03-15
MX2008011165A (es) 2008-09-15
HK1125935A1 (en) 2009-08-21
CA2646409A1 (en) 2007-09-13
AU2007224213B2 (en) 2012-06-14
PE20071311A1 (es) 2007-12-29
WO2007103187A3 (en) 2007-11-01
ATE509928T1 (de) 2011-06-15
MA30284B1 (fr) 2009-03-02
US8263618B2 (en) 2012-09-11
US10081626B2 (en) 2018-09-25
US20130158060A1 (en) 2013-06-20
AU2007224213A1 (en) 2007-09-13
US9663509B2 (en) 2017-05-30
KR101376479B1 (ko) 2014-03-27
US20160176863A1 (en) 2016-06-23
NZ570764A (en) 2011-08-26
US7622508B2 (en) 2009-11-24

Similar Documents

Publication Publication Date Title
BRPI0708490B8 (pt) composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto
ATE502939T1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan- verbindungen als mu-opioid-rezeptorantagonisten
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
BRPI0607015A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
BRPI1014877B8 (pt) compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor ß2 adrenérgico, composição farmacêutica e seu uso
BRPI0508622B8 (pt) compostos de bifenil úteis como antagonistas do receptor muscarínico, composição farmacêutica, processo, medicamento e uso do composto.
MX2009006018A (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
BRPI0518607A2 (pt) derivados de pirrol tendo atividade antagonista de receptor crth2
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
MX2009004780A (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico.
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
BRPI0611202C1 (pt) compostos de benzimidazola-carboxamida como agonistas do receptor 5-ht4
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
SG171681A1 (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BRPI0511999A (pt) compostos como antagonistas de ccr5
CY1115077T1 (el) Κρυσταλλικες μορφες της ενωσης του 8-αζαδικυκλο[3.2.1]οκτανιου
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
BR0308592A (pt) Derivados de piperidina ou 8-azabiciclo [3.2.1] oct-3-il-piperidina, de utilidade como moduladores da atividade do receptor de quimocina (especialmente ccr5)
BRPI0821611A8 (pt) Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu
BRPI0409302A (pt) derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
BRPI0409570A (pt) derivados de 3-benzidrilideno-8-aza-biciclo[3.2.1]octano com atividade receptora de opióides
BRPI0411358A (pt) derivados de 1-(alquilaminoalquil-pirrolidin-/piperidinil)-2,2-difen ilacetamida como antagonistas de receptor muscarìnico
ATE461172T1 (de) Azetidinderivate als antagonisten des muskarinrezeptors

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THERAVANCE BIOPHARMA RANDD IP, LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF